Approaches to the prevention and therapy of ibrutinib-associated bleeding in adult patients
Ibrutinib, an irreversible Bruton tyrosine kinase inhibitor (Btk), is a highly effective drug for treatment a number of B-cell lymphoproliferative disorders and, more recently, graft-versus-host disease. However, a number of potentially adverse events are possible in this therapy, partly related to...
Saved in:
| Main Authors: | E. V. Volchkov, P. A. Zharkov, M. A. Panteleev |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2018-10-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/306 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antithrombotic Therapy in Patients with Malignant Lymphoproliferative Disorders Treated with Ibrutinib
by: EI Emelina, et al.
Published: (2019-09-01) -
İbrutinib Sonrası Gelişen Dev Ekimoz ve Hematom: Olgu Sunumu
by: Aynur Uğur Bilgin, et al.
Published: (2017-03-01) -
Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia
by: EA Nikitin, et al.
Published: (2017-07-01) -
Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia
by: Elżbieta Iskierka-Jażdżewska, et al.
Published: (2025-01-01) -
Intermediate Results of Prospective Observational Study: The 2-year Experience of Ibrutinib Therapy in Relapsed/Refractory Mantle Cell Lymphoma in Clinical Practice
by: VI Vorob’ev, et al.
Published: (2019-03-01)